Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures
Gespeichert in:
| Veröffentlicht in: | Journal of the European Academy of Dermatology and Venereology 2023-11, Vol.37 (11), p.e1307-e1309 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e1309 |
|---|---|
| container_issue | 11 |
| container_start_page | e1307 |
| container_title | Journal of the European Academy of Dermatology and Venereology |
| container_volume | 37 |
| creator | Reguiai, Z Becherel, P A Fougerousse, A C Chaby, G Perrot, J L Begon, E Jacobzone-Lévêque, C Boulard, C Badaoui, A Poreaux, C David, L Quiles-Tsimaratos, N Lons-Danic, D Fite, C Liegeon, A-L Patchinsky, A Parier, J Garcia, C Estève, E Mohty, R Mery-Bossard, L Maccari, F |
| description | |
| doi_str_mv | 10.1111/jdv.19302 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2835272857</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2835272857</sourcerecordid><originalsourceid>FETCH-LOGICAL-c320t-8c49954b1e525340ceb7f9619fb7538c5bd2d46bcb7b572b405ca9eb72b7e0673</originalsourceid><addsrcrecordid>eNo9kctu1DAUhiMEokNhwQugs5xZpPgSTxJ2o1G5lEpUFawj2znuuE3iwcepNO_Hg-GZFryxZH_6_qPzF8V7zi54Ph_v-8cL3komXhQLXq2bUrJGviwWrBXrsm1Ve1a8IbpnjHGumtfFmawrrqRoFsWfKz3NBA9-0oTgp503PoVIsLzafPcrcCFC2iGkiDqNOCUIDnQKe2-hxzjq5JOnT5C_h3LwDqHXSUOYAJ3zVtsD6KkH0g7TIfth8He7k-RovdnprLDh0d_5QU8W4dbTA2yIkOiUtg3j6FNChOXN7Wa7ykE2P-HUYw8japoj0tvildMD4bvn-7z49fny5_Zref3jy7ft5rq0UrBUNrbKy6gMRyWUrJhFU7t2zVtnaiUbq0wv-mptrKmNqoWpmLK6zZAwNbJ1Lc-L5ZN3H8PvGSl1oyeLQx4dw0ydaKQStWjUEV09oTYGooiu20c_6njoOOuOpXW5tO5UWmY_PGtnM2L_n_zXkvwLNmCVMA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2835272857</pqid></control><display><type>article</type><title>Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures</title><source>Wiley Online Library</source><creator>Reguiai, Z ; Becherel, P A ; Fougerousse, A C ; Chaby, G ; Perrot, J L ; Begon, E ; Jacobzone-Lévêque, C ; Boulard, C ; Badaoui, A ; Poreaux, C ; David, L ; Quiles-Tsimaratos, N ; Lons-Danic, D ; Fite, C ; Liegeon, A-L ; Patchinsky, A ; Parier, J ; Garcia, C ; Estève, E ; Mohty, R ; Mery-Bossard, L ; Maccari, F</creator><creatorcontrib>Reguiai, Z ; Becherel, P A ; Fougerousse, A C ; Chaby, G ; Perrot, J L ; Begon, E ; Jacobzone-Lévêque, C ; Boulard, C ; Badaoui, A ; Poreaux, C ; David, L ; Quiles-Tsimaratos, N ; Lons-Danic, D ; Fite, C ; Liegeon, A-L ; Patchinsky, A ; Parier, J ; Garcia, C ; Estève, E ; Mohty, R ; Mery-Bossard, L ; Maccari, F</creatorcontrib><identifier>ISSN: 0926-9959</identifier><identifier>EISSN: 1468-3083</identifier><identifier>DOI: 10.1111/jdv.19302</identifier><identifier>PMID: 37415328</identifier><language>eng</language><publisher>England</publisher><ispartof>Journal of the European Academy of Dermatology and Venereology, 2023-11, Vol.37 (11), p.e1307-e1309</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c320t-8c49954b1e525340ceb7f9619fb7538c5bd2d46bcb7b572b405ca9eb72b7e0673</citedby><cites>FETCH-LOGICAL-c320t-8c49954b1e525340ceb7f9619fb7538c5bd2d46bcb7b572b405ca9eb72b7e0673</cites><orcidid>0000-0002-2850-867X ; 0000-0003-4844-3559</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37415328$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reguiai, Z</creatorcontrib><creatorcontrib>Becherel, P A</creatorcontrib><creatorcontrib>Fougerousse, A C</creatorcontrib><creatorcontrib>Chaby, G</creatorcontrib><creatorcontrib>Perrot, J L</creatorcontrib><creatorcontrib>Begon, E</creatorcontrib><creatorcontrib>Jacobzone-Lévêque, C</creatorcontrib><creatorcontrib>Boulard, C</creatorcontrib><creatorcontrib>Badaoui, A</creatorcontrib><creatorcontrib>Poreaux, C</creatorcontrib><creatorcontrib>David, L</creatorcontrib><creatorcontrib>Quiles-Tsimaratos, N</creatorcontrib><creatorcontrib>Lons-Danic, D</creatorcontrib><creatorcontrib>Fite, C</creatorcontrib><creatorcontrib>Liegeon, A-L</creatorcontrib><creatorcontrib>Patchinsky, A</creatorcontrib><creatorcontrib>Parier, J</creatorcontrib><creatorcontrib>Garcia, C</creatorcontrib><creatorcontrib>Estève, E</creatorcontrib><creatorcontrib>Mohty, R</creatorcontrib><creatorcontrib>Mery-Bossard, L</creatorcontrib><creatorcontrib>Maccari, F</creatorcontrib><title>Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures</title><title>Journal of the European Academy of Dermatology and Venereology</title><addtitle>J Eur Acad Dermatol Venereol</addtitle><issn>0926-9959</issn><issn>1468-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo9kctu1DAUhiMEokNhwQugs5xZpPgSTxJ2o1G5lEpUFawj2znuuE3iwcepNO_Hg-GZFryxZH_6_qPzF8V7zi54Ph_v-8cL3komXhQLXq2bUrJGviwWrBXrsm1Ve1a8IbpnjHGumtfFmawrrqRoFsWfKz3NBA9-0oTgp503PoVIsLzafPcrcCFC2iGkiDqNOCUIDnQKe2-hxzjq5JOnT5C_h3LwDqHXSUOYAJ3zVtsD6KkH0g7TIfth8He7k-RovdnprLDh0d_5QU8W4dbTA2yIkOiUtg3j6FNChOXN7Wa7ykE2P-HUYw8japoj0tvildMD4bvn-7z49fny5_Zref3jy7ft5rq0UrBUNrbKy6gMRyWUrJhFU7t2zVtnaiUbq0wv-mptrKmNqoWpmLK6zZAwNbJ1Lc-L5ZN3H8PvGSl1oyeLQx4dw0ydaKQStWjUEV09oTYGooiu20c_6njoOOuOpXW5tO5UWmY_PGtnM2L_n_zXkvwLNmCVMA</recordid><startdate>20231101</startdate><enddate>20231101</enddate><creator>Reguiai, Z</creator><creator>Becherel, P A</creator><creator>Fougerousse, A C</creator><creator>Chaby, G</creator><creator>Perrot, J L</creator><creator>Begon, E</creator><creator>Jacobzone-Lévêque, C</creator><creator>Boulard, C</creator><creator>Badaoui, A</creator><creator>Poreaux, C</creator><creator>David, L</creator><creator>Quiles-Tsimaratos, N</creator><creator>Lons-Danic, D</creator><creator>Fite, C</creator><creator>Liegeon, A-L</creator><creator>Patchinsky, A</creator><creator>Parier, J</creator><creator>Garcia, C</creator><creator>Estève, E</creator><creator>Mohty, R</creator><creator>Mery-Bossard, L</creator><creator>Maccari, F</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2850-867X</orcidid><orcidid>https://orcid.org/0000-0003-4844-3559</orcidid></search><sort><creationdate>20231101</creationdate><title>Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures</title><author>Reguiai, Z ; Becherel, P A ; Fougerousse, A C ; Chaby, G ; Perrot, J L ; Begon, E ; Jacobzone-Lévêque, C ; Boulard, C ; Badaoui, A ; Poreaux, C ; David, L ; Quiles-Tsimaratos, N ; Lons-Danic, D ; Fite, C ; Liegeon, A-L ; Patchinsky, A ; Parier, J ; Garcia, C ; Estève, E ; Mohty, R ; Mery-Bossard, L ; Maccari, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c320t-8c49954b1e525340ceb7f9619fb7538c5bd2d46bcb7b572b405ca9eb72b7e0673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reguiai, Z</creatorcontrib><creatorcontrib>Becherel, P A</creatorcontrib><creatorcontrib>Fougerousse, A C</creatorcontrib><creatorcontrib>Chaby, G</creatorcontrib><creatorcontrib>Perrot, J L</creatorcontrib><creatorcontrib>Begon, E</creatorcontrib><creatorcontrib>Jacobzone-Lévêque, C</creatorcontrib><creatorcontrib>Boulard, C</creatorcontrib><creatorcontrib>Badaoui, A</creatorcontrib><creatorcontrib>Poreaux, C</creatorcontrib><creatorcontrib>David, L</creatorcontrib><creatorcontrib>Quiles-Tsimaratos, N</creatorcontrib><creatorcontrib>Lons-Danic, D</creatorcontrib><creatorcontrib>Fite, C</creatorcontrib><creatorcontrib>Liegeon, A-L</creatorcontrib><creatorcontrib>Patchinsky, A</creatorcontrib><creatorcontrib>Parier, J</creatorcontrib><creatorcontrib>Garcia, C</creatorcontrib><creatorcontrib>Estève, E</creatorcontrib><creatorcontrib>Mohty, R</creatorcontrib><creatorcontrib>Mery-Bossard, L</creatorcontrib><creatorcontrib>Maccari, F</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reguiai, Z</au><au>Becherel, P A</au><au>Fougerousse, A C</au><au>Chaby, G</au><au>Perrot, J L</au><au>Begon, E</au><au>Jacobzone-Lévêque, C</au><au>Boulard, C</au><au>Badaoui, A</au><au>Poreaux, C</au><au>David, L</au><au>Quiles-Tsimaratos, N</au><au>Lons-Danic, D</au><au>Fite, C</au><au>Liegeon, A-L</au><au>Patchinsky, A</au><au>Parier, J</au><au>Garcia, C</au><au>Estève, E</au><au>Mohty, R</au><au>Mery-Bossard, L</au><au>Maccari, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures</atitle><jtitle>Journal of the European Academy of Dermatology and Venereology</jtitle><addtitle>J Eur Acad Dermatol Venereol</addtitle><date>2023-11-01</date><risdate>2023</risdate><volume>37</volume><issue>11</issue><spage>e1307</spage><epage>e1309</epage><pages>e1307-e1309</pages><issn>0926-9959</issn><eissn>1468-3083</eissn><cop>England</cop><pmid>37415328</pmid><doi>10.1111/jdv.19302</doi><orcidid>https://orcid.org/0000-0002-2850-867X</orcidid><orcidid>https://orcid.org/0000-0003-4844-3559</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0926-9959 |
| ispartof | Journal of the European Academy of Dermatology and Venereology, 2023-11, Vol.37 (11), p.e1307-e1309 |
| issn | 0926-9959 1468-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2835272857 |
| source | Wiley Online Library |
| title | Janus kinase inhibitors (JAKi) for the treatment of atopic dermatitis: real-life data on efficacy and safety in light of the Pharmacovigilance Risk Assessment Committee (PRAC) recommended measures |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A50%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Janus%20kinase%20inhibitors%20(JAKi)%20for%20the%20treatment%20of%20atopic%20dermatitis:%20real-life%20data%20on%20efficacy%20and%20safety%20in%20light%20of%20the%20Pharmacovigilance%20Risk%20Assessment%20Committee%20(PRAC)%20recommended%20measures&rft.jtitle=Journal%20of%20the%20European%20Academy%20of%20Dermatology%20and%20Venereology&rft.au=Reguiai,%20Z&rft.date=2023-11-01&rft.volume=37&rft.issue=11&rft.spage=e1307&rft.epage=e1309&rft.pages=e1307-e1309&rft.issn=0926-9959&rft.eissn=1468-3083&rft_id=info:doi/10.1111/jdv.19302&rft_dat=%3Cproquest_cross%3E2835272857%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2835272857&rft_id=info:pmid/37415328&rfr_iscdi=true |